Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine Dosing Interval
NCT00000209Phase 2Completed
- Sponsor
- National Institute on Drug Abuse
- Start
- Nov 1992
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of buprenorphine in opioid use disorder (OUD), sponsored by National Institute on Drug Abuse. Primary endpoints: Drug use, Withdrawal symptoms and 1 more. Started Nov 1992; status: completed.
02
Drugs
buprenorphine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT00000209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000209.